Abstract During SARS-CoV-2 infection, the innate immune response can be inhibited or
delayed, and the subsequent persistent viral replication can induce emergency signals that …

Myeloproliferative neoplasms are associated with increased risk for thrombotic
complications. These conditions most commonly involve somatic mutations in genes that …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Myelofibrosis (MF) is the deadliest form of myeloproliferative neoplasm (MPN). The JAK
inhibitor Ruxolitinib can reduce constitutional symptoms but it does not substantially improve …

Myeloproliferative neoplasms (MPNs), a group of malignant hematological disorders, occur
as a consequence of somatic mutations in the hematopoietic stem cell compartment and …

Despite distinct clinical entities, the myeloproliferative neoplasms (MPN) share
morphological similarities, propensity to thrombotic events and leukemic evolution, and a …

The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive
for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by …

Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the
erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering …

The process of platelet production has so far been understood to be a 2-stage process:
megakaryocyte maturation from hematopoietic stem cells followed by proplatelet formation …

Myeloproliferative neoplasms (MPN) are chronic stem cell disorders characterized by
enhanced proliferation of myeloid cells, immune deregulation, and drug resistance. JAK2 …